The U.S. Food and Drug Administration (FDA) announced a new crackdown targeting telehealth companies like Hims & Hers and manufacturers of weight loss drugs for misleading advertising practices.

For the first time, federal health officials are focusing on telehealth platforms promoting unofficial versions of prescription drugs, including popular obesity medications.

The big picture: Last week the FDA sent over 100 letters to drugmakers and online prescribing firms warning against false and misleading promotional claims. • Hims & Hers, which built a multibillion-dollar business around selling lower-cost, compounded versions of FDA-approved weight loss drugs like Wegovy and Ozempic, was specifically called out. • The FDA letter accused Hims of implying their compounded products contain

See Full Page